F S&P 500
5,205.75 -7.00 (-0.13%) F Dow Jones
39,161.00 -34.00 (-0.09%) F Nasdaq
18,150.00 -36.50 (-0.20%) E-mini Russell 2000 Index Futur
2,059.20 -5.60 (-0.27%) Petróleo
79.40 +0.41 (+0.52%) Oro
2,325.30 +3.00 (+0.13%)
Nuvectis Pharma, Inc. (NVCT)
Fuera de horario:
Nuvectis Pharma, Inc.
1 Bridge Plaza
Suite 275
Fort Lee, NJ 07024
United States
201 614 3150
https://www.nuvectis.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 13
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & President | 1.12M | N/D | 1966 |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive VP, Chief Scientific & Business Officer | 705.5k | N/D | 1967 |
| Mr. Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 705.5k | N/D | 1984 |
Descripción
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de Nuvectis Pharma, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 8; Junta: 10; Derechos del accionista: 6; Compensación: 9.
